Angiogenesis and Anti-Angiogenesis in Hematological Malignancies

Exploring the critical role of angiogenesis in tumor progression and metastasis, this book features the latest and most promising anti-angiogenesis molecules now being deployed in the battle against hematological malignancies such as leukemia and lymphoma.

It has been generally accepted that angiogenesis is involved in the pathogenesis of hematological malignancies, like acute and chronic leukemia, lymphoma, myelodysplastic syndromes, myeloproliferative neoplasms and multiple myeloma. The extent of angiogenesis in the bone marrow has been correlated with disease burden, prognosis and treatment outcome. Reciprocal positive and negative interactions between tumor cells and bone marrow stromal cells, namely hematopoietic stem cells, fibroblasts, osteoblasts/osteoclasts, endothelial cells, endothelial progenitor cells, T cells, macrophages and mast cells, mediated by an array of cytokines, receptors and adhesion molecules, modulate the angiogenic response in hematological tumors. More recently, it has been emphasized the pro-angiogenic role of the so called vascular niche, indicating a site rich in blood vessels where endothelial cells and mural cells such as pericytes and smooth muscle cells create a microenvironment that affects the behavior of several stem and progenitor cells, in hematological malignancies.

Describes the critical role Angiogenesis plays in tumor progression and metastasis Information on Anti-angiogenesis, one of most promising approaches to the treatment of cancer and metastasis Deals with several anti-angiogenic molecules currently used alone or in combination in the treatment of haematological malignancies Includes supplementary material: sn.pub/extras

Inhalt

Preface.- Introduction.- Angiogenesis in multiple myeloma.- Angiogenesis in lymphomas.- Angiogenesis in leukemia.- Antiangiogenesis.- Concluding remarks.- References.